

A circular black and white stamp. The text "OIPE" is at the top, "JCS90" is at the top right, "OCT 13 1999" is in the center, and "PATENT &amp; TRADEMARK OFFICE" is at the bottom.

Applicant(s):	Lars HOLMGREN et al.		
Application No.:	09/332,063	Group:	1642
Filed:	June 14, 1999	Examiner:	A. Harris
For:	ANGIOGENESIS RELATED MOLECULES		

Docket No.: 3362-101P

RECEIVED  
OCT 14 1999  
TECH CENTER 1600/2900

Sir:

— The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	=	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	32	-	32	=	0	\$ 22	\$0
INDEPENDENT	2	-	3	=	0	\$ 82	\$0
___ FIRST PRESENTATION OF A MULTIPLE CLAIM						\$270	\$0
						TOTAL	\$0

— Petition for \_\_\_\_\_ month(s) extension of time pursuant to 37 CFR §§ 1.17 and 1.136(a). \$ \_\_\_\_\_ for the extension of time.

X No fee is required.

— A check in the amount of \$ \_\_\_\_\_ is enclosed.

— Please charge Deposit Account No. 02-2448 in the amount of \$ \_\_\_\_\_. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By MaryAnne Liotta  
Gerald M. Murphy Jr.  
Reg. No. 28,977  
MaryAnne Liotta, Ph.D.  
Reg. No. 40,069

P. O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

GMM/MAL/LPS  
3362-101P



#6B 10/22/99  
T. Gray

BOX SEQUENCE  
PATENT  
3362-101P

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT(S): Lars HOLMGREN et al.  
APPLICATION NO.: 09/332,063 GROUP: 1642  
FILED: June 14, 1999 EXAMINER: A. Harris  
FOR: ANGIOGENESIS RELATED MOLECULES

RECEIVED

OCT 14 1999

TECH CENTER 1600/290

AMENDMENT

Honorable Commissioner of Patents  
Washington, D.C. 20231

OCT 13 1999

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 17, 1999, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION

Please amend the specification as follows:

Please delete the original Sequence Listing, filed on June 14, 1999. Please insert the Substitute Sequence Listing enclosed herewith immediately after the abstract.

REMARKS

Enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification.